Retatrutide (triple agonist) achieves equivalent weight loss to dual agonists but excels at extreme weight loss targets
Bayesian NMA of 19 RCTs (29,506 adults) shows retatrutide and dual agonists achieve equivalent mean weight loss (~11 kg) surpassing GLP-1RAs (~9 kg), but retatrutide has the highest ≥15% weight loss odds (OR 54.6) and the highest adverse event risk.
Quick Facts
What This Study Found
Mean weight loss: retatrutide ~11 kg, dual agonists ~11 kg, GLP-1RAs ~9 kg. ≥15% weight loss OR: retatrutide 54.6, dual 16.4, GLP-1RA 9.0. T2DM reduced loss by 4-5 kg. Retatrutide: highest AE risk. Female/high-BMI: better outcomes.
Key Numbers
How They Did This
Systematic review and Bayesian NMA of 19 RCTs (29,506 adults, BMI ≥25). Agents: liraglutide, semaglutide, survodutide, tirzepatide, retatrutide vs placebo. Outcomes at ≥36 weeks. Subgroup analyses by diabetes, sex, age, BMI.
Why This Research Matters
This is the first comprehensive NMA comparing all incretin-based weight loss drug classes. It establishes the efficacy hierarchy and identifies which patients respond best to each class.
The Bigger Picture
The obesity drug landscape now has three tiers of incretin-based therapy: single, dual, and triple agonists. This hierarchy enables personalized selection—more potent agents for patients needing extreme weight loss, balanced options for those prioritizing tolerability.
What This Study Doesn't Tell Us
Bayesian NMA has inherent assumptions. Retatrutide data limited (fewer trials). Head-to-head comparisons sparse. Different trial durations and populations.
Questions This Raises
- ?When will retatrutide receive regulatory approval?
- ?Can retatrutide's higher AE risk be managed with dose optimization?
- ?Will quadruple agonists emerge as the next tier?
Trust & Context
- Key Stat:
- OR 54.6 for ≥15% weight loss Retatrutide (triple GLP-1/GIP/glucagon agonist) achieves extreme weight loss targets 54.6x more than placebo—far exceeding single and dual agonists
- Evidence Grade:
- Bayesian NMA of 19 RCTs with 29,506 participants. High-quality evidence synthesis. Retatrutide evidence still limited compared to established agents.
- Study Age:
- Published in 2025.
- Original Title:
- Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
- Published In:
- Obesity (Silver Spring, Md.), 33(11), 2046-2054 (2025)
- Authors:
- Sinha, Binayak(3), Ghosal, Samit(3)
- Database ID:
- RPEP-13622
Evidence Hierarchy
Frequently Asked Questions
What is retatrutide and how is it different?
Retatrutide activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. This "triple agonist" approach produces more extreme weight loss than drugs targeting one (semaglutide) or two (tirzepatide) receptors, but also comes with more side effects.
Which weight loss drug should I choose?
It depends on your goals and tolerance: GLP-1 agonists like semaglutide (~9 kg loss) for moderate weight loss with established safety; dual agonists like tirzepatide (~11 kg) for greater loss with a good safety balance; retatrutide (~11 kg mean but highest extreme loss rates) for ambitious targets, accepting higher side effect risk.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13622APA
Sinha, Binayak; Ghosal, Samit. (2025). Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.. Obesity (Silver Spring, Md.), 33(11), 2046-2054. https://doi.org/10.1002/oby.24360
MLA
Sinha, Binayak, et al. "Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.." Obesity (Silver Spring, 2025. https://doi.org/10.1002/oby.24360
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonist..." RPEP-13622. Retrieved from https://rethinkpeptides.com/research/sinha-2025-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.